We present a new method that combines alchemical transformation with physical pathway to accurately and efficiently compute the absolute binding free energy of receptor-ligand complex. Currently, the double decoupling method (DDM) and the potential of mean force approach (PMF) methods are widely used to compute the absolute binding free energy of biomolecules. The DDM relies on alchemically decoupling the ligand from its environments, which can be computationally challenging for large ligands and charged ligands because of the large magnitude of the decoupling free energies involved. On the other hand, the PMF approach uses physical pathway to extract the ligand out of the binding site, thus avoids the alchemical decoupling of the ligand. However, the PMF method has its own drawback because of the reliance on a ligand binding/unbinding pathway free of steric obstruction from the receptor atoms. Therefore, in the presence of deeply buried ligand functional groups the convergence of the PMF calculation can be very slow leading to large errors in the computed binding free energy. Here we develop a new method called AlchemPMF by combining alchemical transformation with physical pathway to overcome the major drawback in the PMF method. We have tested the new approach on the binding of a charged ligand to an allosteric site on HIV-1 Integrase. After 20 ns of simulation per umbrella sampling window, the new method yields absolute binding free energies within ~1 kcal/mol from the experimental result, whereas the standard PMF approach and the DDM calculations result in errors of ~5 kcal/mol and > 2 kcal/mol, respectively. Furthermore, the binding free energy computed using the new method is associated with smaller statistical error compared with those obtained from the existing methods.
Molecular simulations to investigate the impact of N6-methylation in RNA recognition: Improving accuracy and precision of binding free energy prediction
GROMACS in the cloud: A global supercomputer to speed up alchemical drug design
我们评估了最先进的高性能云计算与传统本地计算集群相比的成本和效率。我们的用例是使用GROMACS分子动力学(MD)工具包进行的原子模拟,重点是炼金术蛋白质-配体结合自由能计算。我们在Amazon Web Services(AWS)云中设置了一个计算集群,该集群将各种不同的实例与英特尔、AMD和ARM CPU结合在一起,其中一些实例具有GPU加速功能。使用代表性的生物分子模拟系统,我们基准测试GROMACS如何在单个实例和多个实例上执行。因此,我们评估哪些实例提供最高的性能,哪些是我们用例中最具成本效益的实例。我们发现,就包括硬件、人员、空间、能源和冷却在内的总成本而言,如果选择了最佳的云实例,在云中生成MD轨迹可以与本地集群一样具有成本效益。此外,我们发现,通过使用全球云资源,可以显着加快蛋白质-配体结合亲和力估计的高通量配体筛选。对于由19,872个独立模拟组成的配体筛选研究,我们使用了研究时云中可用的所有硬件。计算规模不断扩大,在全球范围内同时使用超过4,000个实例、140,000个核心和3,000个GPU达到峰值性能。我们的模拟集合在云中大约两天内完成,而在由数百个节点组成的典型本地集群上完成任务则需要数周时间。我们证明,这样的和类似的研究的成本可以大大降低与检查点重新启动协议,允许使用便宜的现货定价,并通过使用实例类型具有最佳的成本效益。